CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2015.
Mark Perrin, InVivo’s CEO and Chairman, said, “2015 was a year of significant progress for InVivo. At the beginning of the year, we had enrolled a single patient into our pilot study of the Neuro-Spinal Scaffold™.
Mark Perrin, InVivo’s CEO and Chairman, said, “2015 was a year of significant progress for InVivo. At the beginning of the year, we had enrolled a single patient into our pilot study of the Neuro-Spinal Scaffold™.
